Notícias e Atividades da Longeveron

Longeveron é uma empresa listada sob o símbolo LGVN (US).

Veja o organograma con seus 19 executivos principais

Biografias mais buscadas da Longeveron

• Stephen Willard, Chief Executive Officer
• Rock Soffer, Director
• Ursula Ungaro, Director

Recentes movimentos de executivos em Longeveron

• Marie Washburn ingressará na Companhia como Chief Financial Officer em 13 de jul. de 2026  (Notícia publicada em 7 de julho de 2026).
• Lisa Locklear, Executive Vice President and Chief Financial Officer, deixará a Companhia em 13 de jul. de 2026  (Notícia publicada em 7 de julho de 2026).
• Stephen Willard, ingressou na Companhia como Chief Executive Officer  (Notícia publicada em 18 de fevereiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Longeveron.

Longeveron possui 2.430 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Tempus has announced the acquisition of Personalis  (publicado em 20 de julho de 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Longeveron

• Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
• Longeveron® Appoints Marie Washburn as Chief Financial Officer
• New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
• Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
• Longeveron to Present at BIO International Convention 2026
• Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
• Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
• Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
• Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
• Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
• View more press releases Close

Redes sociais sobre Longeveron

• Longeveron na Wikipedia, Google News e Yahoo Finance
• Longeveron na LinkedIn, X (Twitter) e YouTube